BRPI0918419A2 - nova formulação anticorpo - Google Patents

nova formulação anticorpo

Info

Publication number
BRPI0918419A2
BRPI0918419A2 BRPI0918419A BRPI0918419A BRPI0918419A2 BR PI0918419 A2 BRPI0918419 A2 BR PI0918419A2 BR PI0918419 A BRPI0918419 A BR PI0918419A BR PI0918419 A BRPI0918419 A BR PI0918419A BR PI0918419 A2 BRPI0918419 A2 BR PI0918419A2
Authority
BR
Brazil
Prior art keywords
antibody formulation
new antibody
new
formulation
antibody
Prior art date
Application number
BRPI0918419A
Other languages
English (en)
Inventor
Hans-Christian Mahler
Oliver Boris Stauch
Ulla Grauschopf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0918419A2 publication Critical patent/BRPI0918419A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0918419A 2008-09-19 2009-09-09 nova formulação anticorpo BRPI0918419A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164746 2008-09-19
PCT/EP2009/061692 WO2010031720A2 (en) 2008-09-19 2009-09-09 Novel antibody formulation

Publications (1)

Publication Number Publication Date
BRPI0918419A2 true BRPI0918419A2 (pt) 2015-11-24

Family

ID=41231968

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918419A BRPI0918419A2 (pt) 2008-09-19 2009-09-09 nova formulação anticorpo

Country Status (16)

Country Link
US (4) US20100074903A1 (pt)
EP (1) EP2328559B1 (pt)
JP (2) JP5524967B2 (pt)
KR (2) KR20140019035A (pt)
CN (1) CN102159194A (pt)
AU (1) AU2009294680A1 (pt)
BR (1) BRPI0918419A2 (pt)
CA (1) CA2736198A1 (pt)
CL (1) CL2011000561A1 (pt)
ES (1) ES2531385T3 (pt)
IL (1) IL211190A0 (pt)
MX (1) MX2011002402A (pt)
PE (1) PE20110302A1 (pt)
SG (1) SG2014011365A (pt)
WO (1) WO2010031720A2 (pt)
ZA (1) ZA201101343B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2789061A1 (en) 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
KR102276161B1 (ko) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
AR090244A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 抗プロラクチン受容体抗体製剤
SG10201803178UA (en) * 2013-10-24 2018-05-30 Astrazeneca Ab Stable, aqueous antibody formulations
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
WO2017132827A1 (en) * 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7177777B2 (ja) * 2017-01-11 2022-11-24 セルトリオン, インク. 安定した液体製剤
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN116963775A (zh) * 2021-03-03 2023-10-27 爱乐科斯公司 抗siglec-8抗体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
DE69226531T2 (de) 1991-09-30 1999-05-06 Biogen Inc Hemmung von Gefässverengung unter Verwendung von anti-PADGEM Antikörpern.
DE69332881T2 (de) 1992-05-05 2004-01-29 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendung
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Igg 항체의 안정한 액상 약학 제형물
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
WO2006096490A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
KR20080098504A (ko) * 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
BRPI0721097A2 (pt) * 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta

Also Published As

Publication number Publication date
ZA201101343B (en) 2011-11-30
EP2328559B1 (en) 2015-01-07
CN102159194A (zh) 2011-08-17
US20130209478A1 (en) 2013-08-15
CL2011000561A1 (es) 2011-09-02
WO2010031720A3 (en) 2010-09-23
AU2009294680A1 (en) 2010-03-25
KR20110047232A (ko) 2011-05-06
US20100074903A1 (en) 2010-03-25
JP2014094958A (ja) 2014-05-22
ES2531385T3 (es) 2015-03-13
EP2328559A2 (en) 2011-06-08
IL211190A0 (en) 2011-04-28
CA2736198A1 (en) 2010-03-25
JP5524967B2 (ja) 2014-06-18
JP2012502942A (ja) 2012-02-02
US20140093512A1 (en) 2014-04-03
PE20110302A1 (es) 2011-05-21
MX2011002402A (es) 2011-04-05
KR20140019035A (ko) 2014-02-13
US20120321638A1 (en) 2012-12-20
SG2014011365A (en) 2014-05-29
WO2010031720A2 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
NL301152I2 (nl) satralizumab
BRPI0918419A2 (pt) nova formulação anticorpo
DK3072906T3 (da) Antistofformulering
BRPI0907237A2 (pt) Anticorpo anti-cldn6
DK2234600T3 (da) Antistofformulering
BRPI1006519A2 (pt) formulação de anticorpos
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0908269A2 (pt) aplicador
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0907376A2 (pt) Fotobiorretador
DK2252395T3 (da) Afsvovlingsmaterialer
FI20080462A0 (fi) Einespakkaus
BRPI0917231A2 (pt) composição
FI8206U1 (fi) Kanylointisimulantti
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI0907522A2 (pt) biarlamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
BRPI0914098A2 (pt) biosensor
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0912769A2 (pt) anticorpos anti-pirb
FI20086190A (fi) Kenkäpuristinhihna
DK2382224T3 (da) Metalhydracid-materialer
AT507449A3 (de) Dämmstoffbefestiger
DK2254963T3 (da) Kerne-skal-flowforbedrer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.